In this episode, Dr Krystyna de Lange continues the conversation on menopause with Dr Marita Long, discussing pharmacological management for troublesome menopausal symptoms.

Dr Long begins by addressing non-hormonal pharmacological options for women who either cannot use hormones or choose not to. She covers medications such as SNRIs (Venlafaxine or Desvenlafaxine), SSRIs, Gabapentin, Clonidine, and introduces Fesolinatant, a new treatment option recently approved by the TGA.

They then shift to hormonal menopause replacement therapy (MHT). Dr Long outlines which patients are suitable for hormonal therapy and which are not. She explains the different regimes, including cyclical and continuous treatment, emphasising the importance of matching therapy to the patient's specific needs based on their menopausal status and the presence of a uterus.

Covering the variety of hormone delivery methods available, such as oral, patches, and gels, noting the benefits and considerations of each form. Highlighting the importance of tailoring the approach to the patient's risk profile, particularly concerning cardiovascular health and breast cancer risk.

They concluded with Dr Long recommending effective resources such as the Australasian Menopause Society and Jean Hales for Women's Health, providing valuable information for both healthcare professionals and patients.

The Good GP Podcast is a proud member of the Talking HealthTech Podcast Network - the premier audio destination for cutting-edge insights and thought leadership in healthcare delivery, innovation, digital health, healthcare ICT, and commercialisation. Learn more at www.talkinghealthtech.com/podcast/network.

If you have any questions or would like to contact The Good GP, send an email to thegoodgp@gmail.com.

Mentioned in this episode:

Proudly supported by Medtech Global:

The Good GP Podcast is sponsored by Medtech Global, they help GPs be GPs by working with clinicians in Australia and New Zealand to develop Patient Management Systems and healthcare technology. Visit the link for more information:

Medtech Global